Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

CONCLUSIONS: Despite some early, largely transient increases in gastrointestinal symptoms, patients with OC treated with niraparib first-line maintenance therapy reported no worsening in overall HRQoL.PMID:38325276 | DOI:10.1016/j.ygyno.2024.01.021

Source: Gynecologic Oncology - February 7, 2024 Category: Cancer & Oncology Authors: Bhavana Pothuri Sileny Han Dana M Chase Florian Heitz Robert A Burger Lydia Gaba Linda Van Le Eva Guerra David Bender Jacob Korach Noelle Cloven Cristina Churruca Philippe Follana Paul DiSilvestro Jean-Fran çois Baurain Kris Jardon Carmela Pisano Ulla Pe Source Type: research